- All > Medicine Information and Evidence for Policy > Medicines Policy
- All > Quality and Safety: Medicines > Regulatory Support
- Keywords > domestic production - essential medicines
- Keywords > essential medicines - concept
- Keywords > import/export authorization
- Keywords > industrial policy
- Keywords > law
- Keywords > local production capacity
- Keywords > market control
- Keywords > medicine control
- Keywords > pharmaceutical industry
- Keywords > regulatory control
(1987; 2 pages)
The 1982 New Drug Policy and Drug Control Ordinance of Bangladesh received major backlash from industry and other sectors who felt their interests were not accounted for by the policy. To combat the opposition, the Bangladesh Association of Pharmaceutical Industries (BAPI) published an article in the New Nation newspaper detailing the benefits that the public and private sector have gained from the new policies. This article, written by BAPI Secretary General A.K.M. Shahidullah, was reprinted in the fifth edition of the Essential Drugs Monitor. According to Shahidullah, the largest benefit of the Drug Control Ordinance is its emphasis on essential drugs. Industry benefits because the need for such drugs is widespread and will only increase, while the public benefits because larger supply means better access to rural or poor communities. Other benefits are that import substitutes are given priority registration under the policy, and that industry recommendations on import restrictions are taken more seriously. Furthermore, imported products share in the market has reduced 5% in four years since new policies’ implementation. The new policy also sparked interest in consumers, and more people began seeking health care. This increase subsequently expanded the pharmaceutical industry. The article concludes by noting that quality assurance can never be sacrificed for low prices.
Abstract written by M. Tobin, 2013.